Answer
Momelotinib (Omjjara) and its major human circulating metabolite M21 inhibit wild-type JAK1 and JAK2 and mutant JAK2 V617F, and potentially inhibit other JAK family members.
Sources for this answer
- Omjjara 150 mg film-coated tabletsGlaxoSmithKline UK · emc · SmPC §5.1 Pharmacodynamic properties · Version 4Document updated
Sources checked